orantinib   Click here for help

GtoPdb Ligand ID: 7816

Synonyms: SU-6668 | TSU-68
PDB Ligand
Compound class: Synthetic organic
Comment: Orantinib is a multi-kinase inhibitor.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 3
Rotatable bonds 4
Topological polar surface area 82.19
Molecular weight 310.13
XLogP 1.88
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES OC(=O)CCc1c(C)[nH]c(c1C)C=C1C(=O)Nc2c1cccc2
Isomeric SMILES OC(=O)CCc1c(C)[nH]c(c1C)/C=C/1\C(=O)Nc2c1cccc2
InChI InChI=1S/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19H,7-8H2,1-2H3,(H,20,23)(H,21,22)/b14-9-
No information available.
Summary of Clinical Use Click here for help
The only Phase 3 study designed to evaluate orantinib's efficacy (NCT01465464) was terminated.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Orantinib inhibits several receptor tyrosine kinases including PDGFRβ, VEGFR2, and FGFR1 [2], but does not inhibit EGFR [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01465464 Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma Phase 3 Interventional Taiho Pharmaceutical Co., Ltd.